Inflammatory Modulation Articles & Analysis

2 news found

Stemedica Opens Enrollment in Phase II Clinical Trial for COVID-19 A Phase II Study in Patients with Moderate to Severe ARDS Using GMP, Allogeneic, Bone Marrow-Derived, Ischemic-Tolerant Mesenchymal Stem Cells

Stemedica Cell Technologies, Inc. (“Stemedica”), a San Diego-based biotech company specializing in the manufacture of clinical grade stem cells, announces enrollment of patients for its study entitled “A Phase II, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Patients With ...

Aug. 5, 2021

ByStemedica Cell Technologies, Inc.

Stemedica Signs License Agreement with Pulthera, LLC for all Respiratory Indications including those related to COVID-19

Stemedica Cell Technologies, Inc. (“Stemedica”), a San Diego-based biotech company specializing in the manufacture of clinical grade stem cells, announced today that it has signed a Licensing Agreement with Pulthera, LLC for the rights to use, distribute and sell its mesenchymal stem cell technologies in the treatment of COVID-19 and additional pulmonary conditions. The agreement was ...

May 23, 2021

ByStemedica Cell Technologies, Inc.

Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you